Farmers Trust Co. Has $1.20 Million Position in Kenvue Inc. (NYSE:KVUE)

Farmers Trust Co. trimmed its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 77.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 49,909 shares of the company's stock after selling 167,309 shares during the quarter. Farmers Trust Co.'s holdings in Kenvue were worth $1,197,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its position in Kenvue by 3.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock valued at $5,249,665,000 after purchasing an additional 8,211,748 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Kenvue by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company's stock worth $4,665,908,000 after buying an additional 1,636,741 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in Kenvue by 12.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock valued at $2,085,070,000 after purchasing an additional 10,682,003 shares during the last quarter. Geode Capital Management LLC raised its stake in Kenvue by 3.1% during the 4th quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company's stock valued at $980,989,000 after purchasing an additional 1,391,854 shares during the last quarter. Finally, Franklin Resources Inc. increased its holdings in Kenvue by 61.5% in the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock valued at $912,059,000 after buying an additional 16,269,721 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Down 0.6%

Shares of NYSE:KVUE traded down $0.16 during midday trading on Monday, hitting $23.72. The stock had a trading volume of 6,377,646 shares, compared to its average volume of 16,306,877. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The business's 50-day simple moving average is $23.27 and its 200-day simple moving average is $22.63. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $25.17. The company has a market cap of $45.50 billion, a P/E ratio of 44.78, a PEG ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. The company had revenue of $3.74 billion during the quarter, compared to analysts' expectations of $3.69 billion. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Kenvue's quarterly revenue was down 3.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.28 earnings per share. On average, sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were given a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.46%. Kenvue's payout ratio is presently 149.09%.

Analyst Ratings Changes

A number of research analysts have issued reports on KVUE shares. Barclays upped their target price on shares of Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research report on Monday, May 12th. Citigroup raised their target price on shares of Kenvue from $22.00 to $24.50 and gave the stock a "neutral" rating in a report on Friday, May 9th. Canaccord Genuity Group raised their target price on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Redburn Atlantic began coverage on shares of Kenvue in a report on Thursday, April 10th. They set a "neutral" rating and a $23.50 target price on the stock. Finally, Piper Sandler raised their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a report on Monday, February 24th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $25.33.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.